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Abstract
Background: A crucial impediment to global tuberculosis control is the lack of an accurate, rapid diagnostic test for
detection of patients with active TB. A new, rapid diagnostic method, (Cepheid) Xpert MTB/RIF Assay, is an automated
sample preparation and real-time PCR instrument, which was shown to have good potential as an alternative to current
reference standard sputum microscopy and culture.
Methods: We performed a clinical validation study on diagnostic accuracy of the Xpert MTB/RIF Assay in a TB and HIV
endemic setting. Sputum samples from 292 consecutively enrolled adults from Mbeya, Tanzania, with suspected TB were
subject to analysis by the Xpert MTB/RIF Assay. The diagnostic performance of Xpert MTB/RIF Assay was compared to
standard sputum smear microscopy and culture. Confirmed Mycobacterium tuberculosis in a positive culture was used as a
reference standard for TB diagnosis.
Results: Xpert MTB/RIF Assay achieved 88.4% (95%CI = 78.4% to 94.9%) sensitivity among patients with a positive culture
and 99% (95%CI = 94.7% to 100.0%) specificity in patients who had no TB. HIV status did not affect test performance in 172
HIV-infected patients (58.9% of all participants). Seven additional cases (9.1% of 77) were detected by Xpert MTB/RIF Assay
among the group of patients with clinical TB who were culture negative. Within 45 sputum samples which grew non-
tuberculous mycobacteria the assay’s specificity was 97.8% (95%CI = 88.2% to 99.9%).
Conclusions: The Xpert MTB/RIF Assay is a highly sensitive, specific and rapid method for diagnosing TB which has potential
to complement the current reference standard of TB diagnostics and increase its overall sensitivity. Its usefulness in
detecting sputum smear and culture negative patients needs further study. Further evaluation in high burden TB and HIV
areas under programmatic health care settings to ascertain applicability, cost-effectiveness, robustness and local acceptance
are required.
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Introduction
Tuberculosis (TB) continues to kill 1.8 million people annually.
Progress towards global TB control has remained elusive despite
intensified standard measures of TB control [1]. National TB
control programmes in most TB and TB/HIV endemic countries
continue to rely largely on century old, antiquated and inaccurate
tools such as direct smear microscopy, solid culture, chest
radiography and tuberculin skin testing [2]. Currently, there is
no rapid, point-of-care test that allows early detection of active TB
at the peripheral health clinic level. Thus many patients with
active TB, especially in TB and HIV endemic areas are either
treated based on clinical grounds and without microbiological
proof of TB-infection or remain undiagnosed and are continuing
to spread the disease in the community [3]. The need for a more
accurate, point-of-care TB diagnostic test that is applicable in TB
and HIV endemic areas is crucial for achieving global TB control.
Modeling studies show that new diagnostics for TB and multi-drug
resistant TB (MDR-TB) may have an important impact at the
population level in disease endemic countries [4]. Over the past
decade the TB diagnostics pipeline has expanded, with several
technologies showing promise [2]. Among them are new and
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simplified PCR-based methods which have been shown to detect
Mycobacterium tuberculosis (Mtb) and resistance to rifampicin with
good sensitivity and specificity directly from positive cultures or
clinical specimens. Current large-scale roll-out of liquid culture
promises to improve sensitivity and drug susceptibility testing
(DST). However, caution should be applied in settings where non-
tuberculous mycobacteria (NTM) are common environmental
microorganisms, such as in sub-Saharan Africa [5,6] because
detection of NTM growth could lead to a false diagnosis of TB.
The World Health Organization (WHO) is ensuring that new TB
diagnostic policies are evidence-based [7], and in alignment with the
GRADE approach to guideline development [8]. In 2009, the first
technical data were announced from an automated molecular test
for TB, the Xpert MTB/RIF Assay co-developed by the Foundation
for Innovative New Diagnostics, Cepheid (Sunnyvale, Calif, USA),
and the University ofMedicine andDentistry of New Jersey [9]. This
assay, which was CE (Conformite´ Europe´enne) marked in 2009,
avoids many of the pitfalls of conventional nucleic acid amplification
tests and can be performed by staff with minimal training, and used
for case detection or MDR screening at the same time. Thus this
assay is said to specifically detect Mtb and rifampicin resistance from
one sputum sample within 2 hours. It is said to constitute a greatly
simplified nucleic acid amplification test which can be performed by
any laboratory or clinical personnel after minimal introductive
training [9]. The Xpert MTB/RIF Assay is a single-use sample
processing cartridge system that holds all required sample
preparation and real-time PCR reagents and hosts the whole PCR
reaction. The assay has recently undergone performance evaluation
on respiratory specimens [9,10,11,12] as well as on non-respiratory
samples [11] [13], one of them was a multi-country ‘technical’
evaluation which showed the Xpert MTB/RIF Assay to have high
sensitivity and specificity [10], producing results in 2 hours. Since
December 2010 WHO recommends the use of Xpert MTB/RIF
Assay as initial diagnostic test for TB diagnosis in patients with
suspected MDR-TB or TB in association with HIV- infection [14].
In this cohort- study we wanted to validate the diagnostic accuracy of
the Xpert MTB/RIF Assay in our setting, an area with high
prevalence of TB and HIV. We compared the results of the Xpert
MTB/RIF Assay to sputum smear and culture as standard
diagnostic methods on samples from HIV-infected and HIV-
uninfected patients with suspected TB, from Mbeya, Tanzania.
Methods
Ethics approval
The study was approved by the local Mbeya Medical Research
and Ethics Committee and the National Institute of Medical
Research (NIMR) Ethics Committee. Written informed consent
was obtained from all participants or their legal representative for
use of their sputum for TB diagnostics research.
Study setting
The study was conducted according to the principles expressed
in the Declaration of Helsinki as revised in 2000 at the Mbeya
Referral Hospital in the Mbeya region, south west Tanzania which
has a high burden of TB and HIV.
Recruitment of participants
Three hundred consecutive patients with symptoms suggestive
of pulmonary TB who presented to the Mbeya Referral Hospital
between July 2007 and September 2007 were interviewed for
enrolment into the study. After informed consent, recruitment
procedures comprised interviews regarding medical history,
clinical examination, chest radiography, blood sample collection
and HIV pre- and post-test counseling of participants. Eight
patients were excluded from the study because they either were
incapable to produce sputum at recruitment or were lost to follow
up during recruitment procedures.
Sputum samples collected per patient
All 292 study patients had three sputum samples collected (one
spot sample, one morning sample and another spot sample,
making a total of three for analyses).
Sputum sample processing
Sputum samples were split into two aliquots, one of which was
stored at 280uC. The other aliquot was processed for standard
sputum microscopy after Ziehl-Neelsen staining and culture. Sputa
were decontaminated by the NALC-NaOH method and the
resulting pellet was examined for acid fast bacilli (AFB) by
microscopy and culture, always both on Lowenstein-Jensen media
(LJ) and BACTEC MGIT (MGIT) 960 liquid culture (BAC-
TECTM MGIT, Becton Dickinson, Sparks, USA) in parallel, using
standard protocols. The AFB smear grade was defined following
the International Union against Tuberculosis and Lung Disease
scale: Scanty (1–9/100 fields), 1+(10–99/100 fields), 2+(1–10/100
fields) and 3+(.10/field) [15]. A patient was considered smear
positive if at least one smear was graded scanty or higher. Species
determination of cultured organisms was performed by GenotypeH
Mycobacterium MTBC, CM and AS tests (Hain Lifescience,
Nehren, Germany). Rifampicin susceptibility was tested using
SIRE test kits in the BACTEC MGIT system [16].
The microbiology and the molecular biology laboratory of
NIMR-Mbeya Medical Research Programme operate in accor-
dance with standardized protocols and quality control and quality
assurance procedures.
Patient classification
Participants were classified into 5 groups according to their
microbiological, radiological and clinical findings at enrollment
and follow up visits:
TB (S+/C+). Patients with microbiologically confirmed
pulmonary TB who had at least one positive sputum-smear (S+)
and one Mtb-positive sputum culture (C+) sample.
TB (S2/C+). Patients with microbiologically confirmed
pulmonary TB who were smear-negative but had at least one
Mtb- positive culture sample.
No TB (C2). Patients with bacterial chest infection who were
sputum smear- and culture-negative and responded to antibiotic
treatment with amoxicillin, co-trimoxazole, or cefpodoxime with
full recovery. No anti-TB treatment was given to these patients.
Clinical TB (C2). Patients who were classified as having
pulmonary TB (despite lacking microbiological confirmation of
Mtb) based on clinical and radiologic findings after failure to
respond to two courses of oral antibiotics comprising amoxicillin,
co-trimoxazole, or cefpodoxime. All patients showed a clear
clinical response to TB treatment in the follow-up.
Indeterminate. Patients, who were lost to clinical follow up
or had no complete set of data (either culture results or radiological
data were unavailable). No anti-TB treatment was accorded.
Patient treatment and follow up
All 292 patients were followed up for a period of 56 days. TB
drug treatment was accorded by the District Leprosy and TB
Coordinator following Tanzanian national guidelines for TB
treatment. Patients diagnosed with HIV infection were referred for
further staging and treatment to the relevant Care and Treatment
Center.
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Analysis of sputum samples by Xpert MTB/RIF Assay
Biobanked sputum samples from 292 patients of all study groups
were subject to analysis using Xpert MTB/RIF Assay during the
period January 2010 to March 2010 at the same TB laboratory at
MMRP. Clinical and laboratory staff involved with this study were
blinded for clinical diagnosis, sputum smear, culture and drug
susceptibility results of the sputa samples. Frozen sputa were
thawed and processed according to the Xpert MTB/RIF Assay
test procedure [9]. Positive results were displayed by Xpert MTB/
RIF Assay as semi-quantitative estimates depending on the Ct
value of the present sample. Lower cycle threshold (Ct) values
represented a higher concentration of Mtb complex (MTBC) DNA
and higher Ct values represented a lower DNA-concentration. A
Ct value of $40 reflected a Mtb- negative sample.
Statistical analysis
For statistical comparison, Mtb culture positivity was used as
reference standard, defined as identification of Mtb in at least one
positive standard sputum culture (either on LJ slopes or MGIT
culture) out of three analysed sputum samples. Statistical analysis
by number or type of sputum samples used by test performed was
run using Stata 11.0 statistics software (Statacorp, College Station,
TX, USA) [17]. Sensitivity and specificity were calculated using
Stata’s ‘‘diagt’’ component. Associations of indicators of AFB
density between Xpert MTB/RIF Assay, sputum smear micros-
copy and culture results were assessed using linear regression and
displayed using Stata graphics.
Results
Time to result and technical aspects
All sample results were obtained within two hours of
commencing the analyses. There were no technical operational
problems encountered with the use of the machine that required
attention.
Classification of the study population
A total of 292 individuals (151 females and 141 males) with a
mean age of 39.2 years (SD=13.8) were classified into five
different groups according to microbiological, radiological and
clinical findings (table 1).
69 (23.6% of 292) patients had microbiologically confirmed
pulmonary TB with Mtb identified in their sputum culture. These
included 51 sputum smear-positive (S+/C+) and 18 smear-
negative (S2/C+) cases. 103 patients (35.3% of 292) were shown
to have no TB (C2). These patients were smear and culture
negative and showed a sustained recovery within 56 days of
receiving antibacterial antibiotic therapy. Out of the remaining
120 patients, 77 (26.4% of 292) were classified as clinical TB-cases
(C2) on clinical and radiological grounds although sputum culture
results were negative for Mtb. All patients in this group received
anti- TB treatment and showed a sustained recovery after 56 days.
Two study participants were smear-positive but culture- negative.
These patients were included into this group due to typical clinical
and radiological findings as well as marked improvement under
anti 2TB therapy. 43 participants (14.7% of 292) were classified
as indeterminate and not included in the final analysis since there
was no clear evidence of mycobacterial or other bacterial infection
in those patients or sufficient data were not available for
classification into one of the other groups.
HIV status of participants
The overall HIV prevalence in the study population was 58.9%
(95%CI=45% to 89.9%). In microbiologically confirmed TB
cases the HIV prevalence (66.7%) in group (S+/C+) was not
statistically different (p-value 0.07) from HIV prevalence (88.9%)
in group (S2/C+).
Diagnostic performance analysis of the Xpert MTB/RIF
Assay per classification group
In table 1 the results of Xpert MTB/RIF Assay as per patient
analysis are depicted according to the patient classification group.
50 out of 51 smear and culture positive patients (S+/C+) were
detected positive by Xpert MTB/RIF assay resulting in a 98%
sensitivity (98% CI= 89.6% to 100.0%) in this group. Only 11 out
of 18 patients with a negative smear and positive culture (S2/C+)
were positive by the assay. Sensitivity was 61.1% (CI= 35.7% to
82.7%) in this group which is statistically different (p-value,0.001)
to the sensitivity of the assay (98%) in group (S+/C+). Among all
103 TB-negative patients (C2) the submitted sputa of one patient
were Xpert MTB/RIF Assay positive, giving the assay a specificity
of 99% ( 95%CI= 94.7% to 100.0%). The corresponding patient
Table 1. Patient classification, HIV prevalence and Xpert MTB/RIF Assay results for each patient group.
Xpert MTB/RIF Assay resulta
Size of group HIV prevalence positive negative
Status Group and definition % of total (n) % in group (n) % in group (n) % in group (n)
Microbiologically confirmed TB TB (S+/C+) 17.5 (51) 66.7 (34) 98.0b (50) 2.0 (1)
TB (S2/C+) 6.2 (18) 88.9 (16) 61.1c (11) 38.9 (7)
No microbiological proof of TB Clinical TB (C2) 26.4 (77) 68.8 (53) 9.1 (7) 90.9 (70)
No TB (C2) 35.3 (103) 48.5 (50) 1.0 (1) 99.0d (102)
Incomplete clinical or microbiological
assessment
Indeterminate 14.7 (43) 44.2 (19) 2.3 (1) 97.7 (42)
Total 100 (292) 58.9 (172) 24.0 (70) 76.0 (222)
a = Xpert MTB/RIF Assay result per patient analysis.
b = sensitivity in this group, 95%CI = 89.6% to 100.0%.
c = sensitivity in this group, 95%CI = 35.7% to 82.7%.
d = specificity in this group, 95%CI = 94.7% to 100.0%.
S+/C+= sputum smear positive and culture positive; S2/C+= sputum smear negative and culture positive; C2= culture negative.
doi:10.1371/journal.pone.0020458.t001
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was HIV-infected and had a previous history of TB and of
receiving anti- TB treatment.
Amongst the 77 participants in the group of Clinical TB (C2)
who had no Mtb- positive sputum culture but a clinical diagnosis of
TB, the Xpert MTB/RIF Assay detected an additional seven
(9.1% of 77) Mtb- positive patient samples. The Ct-values
displayed by GeneXpert for these samples were high (Ct 22–28)
or very high (Ct.28), indicating a low mycobacterial load in the
sputum. Despite the low amplification signal, Xpert MTB/RIF
Assay was consistently positive in the analysis of single or multiple
sputum samples from these seven patients. All seven patients were
HIV-positive and were thus treated for TB based on their clinical
and radiological findings and non-responsiveness to anti-bacterial
antibiotic therapy. None of them had a history of previous TB
diagnosis or treatment. The sputum samples of the remaining 70
(90.9% of 77) participants of this group were Xpert MTB/RIF
Assay negative.
Diagnostic performance of the Xpert MTB/RIF Assay in
per sample analysis and compared to other tests
For all 69 culture positive TB patients (S+/C+ and S2/C+),
and 103 patients defined as TB negative (No TB [C2]), the
diagnostic performance per sample (first spot sample and morning
sample) of all the diagnostic tests alone and their combination were
ascertained; the data is presented in table 2. The reference
standard, on which microbiological confirmed TB diagnosis was
based in this study, was defined as at least one positive sputum
culture for Mtb out of three sputum samples analysed. Compared
to spot sputa the sensitivity of the Xpert MTB/RIF Assay was only
slightly increased in morning sputa showing no statistical
difference (p-value 0.459); 84.1% (95%CI= 73.3% to 91.8%) vs.
88.4% (95%CI=78.4% to 94.9%). Importantly, the overall per
patient sensitivity of 88.4% (95%CI= 78.4% to 94.9%) of the
Xpert MTB/RIF Assay remained the same when three sputa (first
spot sample, morning sample and 2nd spot sample) were analysed.
Table 2. Comparison of Xpert MTB/RIF Assay and other methods with reference standard for both HIV-positive and -negative
participants.
Samples Testa Sensitivity (95%CI); n positive Specificity (95%CI); n negative
Reference Standardb 69 103
One spot sputum
Xpert 84.1 ( 73.3 to 91.8 ); 58 99.0 ( 94.7 to 100 ); 102
Smear only 58.0 ( 45.5 to 69.8 ); 40 100.0 ( 96.5 to 100 ); 103
LJ only 73.9 ( 61.9 to 83.8 ); 51 100.0 ( 96.5 to 100 ); 103
Mgit only 76.8 ( 65.1 to 86.1 ); 53 100.0 ( 96.5 to 100 ); 103
Smear & LJ 84.1 ( 73.3 to 91.8 ); 58 100.0 ( 96.5 to 100 ); 103
Smear, LJ & Mgit 91.3 ( 82.0 to 96.7 ); 63 100.0 ( 96.5 to 100 ); 103
One morning sputum
Xpert 88.4 ( 78.4 to 94.9 ); 61 99.0 ( 94.7 to 100 ); 102
Smear only 66.7 ( 54.3 to 77.6 ); 46 100.0 ( 96.5 to 100 ); 103
LJ only 68.1 ( 55.8 to 78.8 ); 47 100.0 ( 96.5 to 100 ); 103
Mgit only 78.3 ( 66.7 to 87.3 ); 54 100.0 ( 96.5 to 100 ); 103
Smear & LJ 79.7 ( 68.3 to 88.4 ); 55 100.0 ( 96.5 to 100 ); 103
Smear, LJ & Mgit 85.5 ( 75.0 to 92.8 ); 59 100.0 ( 96.5 to 100 ); 103
First two sputa
Xpert 88,4 ( 78.4 to 94.9 ); 61 99.0 ( 94.7 to 100 ); 102
Smear only 71,0 ( 58.8 to 81.3 ); 49 100.0 ( 96.5 to 100 ); 103
LJ only 87,0 ( 76.7 to 93.9 ); 60 100.0 ( 96.5 to 100 ); 103
Mgit only 88,4 ( 78.4 to 94.9 ); 61 100.0 ( 96.5 to 100 ); 103
Smear & LJ 89,9 ( 80.2 to 95.8 ); 62 100.0 ( 96.5 to 100 ); 103
Smear, LJ & Mgit 95,7 ( 87.8 to 99.1 ); 66 100.0 ( 96.5 to 100 ); 103
Per patient analysis (3 sputa)
Xpert 88.4 ( 78.4 to 94.9 ); 61 99.0 ( 94.7 to 100 ); 102
Smear only 73.9 ( 61.9 to 83.8 ); 51 100.0 ( 96.5 to 100 ); 103
LJ only 94.2 ( 85.8 to 98.4 ); 65 100.0 ( 96.5 to 100 ); 103
Mgit only 95.7 ( 87.8 to 99.1 ); 66 100.0 ( 96.5 to 100 ); 103
Smear & LJ 95.7 ( 87.8 to 99.1 ); 66 100.0 ( 96.5 to 100 ); 103
Smear, LJ & Mgit 100.0 ( 94.8 to 100 ); 69 100.0 ( 96.5 to 100 ); 103
aall culture results include speciation test results (for confirmation of Mtb or exclusion of Mtb in case when NTM present).
breference standard for confirmed TB- diagnosis, defined as at least one positive culture (LJ or Mgit) confirmed as Mtb in speciation of per patient analysis; Mtb- negative
defined as all cultures negative (LJ and Mgit) for Mtb in per patient analysis, speciation results included.
Smear = Sputum smear microscopy after ZN-staining; LJ = Loewenstein-Jensen culture on solid media; Mgit = BACTEC MGIT 960 liquid culture.
doi:10.1371/journal.pone.0020458.t002
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In both types of sputa sensitivity of Xpert MTB/RIF Assay was
always higher than that of any other method alone.
Specificity of Xpert MTB/RIF Assay was the same in spot
and morning sputum (99%, 95%CI= 94.7% to 100.0%).
For analysis of 50 HIV-infected patients with a positive TB
culture (S+/C+ and S2/C+) and 50 HIV-infected patients from
the No TB (C2) group, the diagnostic results of the same tests as
above are shown in table 3. In spot sputum the Xpert MTB/RIF
Assay had 82% (95%CI=68.6% to 91.4%) sensitivity compared
to 88% (95%CI=75.7% to 95.5%) sensitivity in morning sputum
which was statistically not different (p-value 0.864). In both types
of sputa specificity was 98% (95%CI=89.4% to 100.0%).
Comparison of quantitative results
An analysis of markers for sputum bacterial load, such as grade
of smear- positivity (figure 1) and time to positivity in MGIT liquid
culture (figure 2), shows good correlation with the quantitative
result of real-time PCR obtained from the Xpert MTB/RIF Assay
(expressed in Cycle threshold (Ct) values - which correlate
inversely with the concentration of target DNA) (figure 1, 2).
Specificity of Xpert MTB/RIF Assay in NTM - positive
specimens
There were 45 patients (15.4% of 292), 24 in the No-TB (C2)
group and 21 in the group of Clinical TB (C2), in whose cultures
grew NTM. The speciation tests of these NTM detected M.
fortuitum (10), M. intracellulare (5), M. celatum I+II (2), M.
scrofulaceum (1) and M. szulgai (1). In 32 cases a final
identification of the NTM was not possible. Only one of these
patients’ sputum samples tested positive by Xpert MTB/RIF
Assay, resulting in an Xpert MTB/RIF Assay specificity of 97.8%
in this group (95%CI= 88.2% to 99.9%).
Drug resistance data on Mtb isolates
All strains of Mtb isolated were drug sensitive. There were no
Mtb strains resistant to RIF or INH when tested by standard drug
Table 3. Comparison of Xpert MTB/RIF Assay and other methods with reference standard in HIV-positives only.
Samples Testa Sensitivity (95%CI); n positive Specificity (95%CI); n negative
Reference Standardb 50 50
One spot sputum
Xpert 82.0 ( 68.6 to 91.4 ); 41 98.0 ( 89.4 to 100 ); 49
Smear only 52.0 ( 37.4 to 66.3 ); 26 100.0 ( 92.9 to 100 ); 50
LJ only 68.0 ( 53.3 to 80.5 ); 34 100.0 ( 92.9 to 100 ); 50
Mgit only 76.0 ( 61.8 to 86.9 ); 38 100.0 ( 92.9 to 100 ); 50
Smear & LJ 78.0 ( 64.0 to 88.5 ); 39 100.0 ( 92.9 to 100 ); 50
Smear, LJ & Mgit 88.0 ( 75.7 to 95.5 ); 44 100.0 ( 92.9 to 100 ); 50
One morning sputum
Xpert 88.0 ( 75.7 to 95.5 ); 44 98.0 ( 89.4 to 100 ); 49
Smear only 60.0 ( 45.2 to 73.6 ); 30 100.0 ( 92.9 to 100 ); 50
LJ only 68.0 ( 53.3 to 80.5 ); 34 100.0 ( 92.9 to 100 ); 50
Mgit only 74.0 ( 59.7 to 85.4 ); 37 100.0 ( 92.9 to 100 ); 50
Smear & LJ 76.0 ( 61.8 to 86.9 ); 38 100.0 ( 92.9 to 100 ); 50
Smear, LJ & Mgit 84.0 ( 70.9 to 92.8 ); 42 100.0 ( 92.9 to 100 ); 50
First two sputa
Xpert 88,0 ( 75,7 to 95,5 ); 44 98,0 ( 89,4 to 100 ); 49
Smear only 66,0 ( 51,2 to 78,8 ); 33 100,0 ( 92,9 to 100 ); 50
LJ only 84,0 ( 70,9 to 92,8 ); 42 100,0 ( 92,9 to 100 ); 50
Mgit only 86,0 ( 73,3 to 94,2 ); 43 100,0 ( 92,9 to 100 ); 50
Smear & LJ 86,0 ( 73,3 to 94,2 ); 43 100,0 ( 92,9 to 100 ); 50
Smear, LJ & Mgit 94,0 ( 83,5 to 98,8 ); 47 100,0 ( 92,9 to 100 ); 50
Per patient analysis (3 sputa)
Xpert 88.0 ( 75.7 to 95.5 ); 44 98.0 ( 89.4 to 100 ); 49
Smear only 68.0 ( 53.3 to 80.5 ); 34 100.0 ( 92.9 to 100 ); 50
LJ only 92.0 ( 80.8 to 97.8 ); 46 100.0 ( 92.9 to 100 ); 50
Mgit only 96.0 ( 86.3 to 99.5 ); 48 100.0 ( 92.9 to 100 ); 50
Smear & LJ 94.0 ( 83.5 to 98.8 ); 47 100.0 ( 92.9 to 100 ); 50
Smear, LJ & Mgit 100.0 ( 92.9 to 100 ); 50 100.0 ( 92.9 to 100 ); 50
aall culture results include speciation test results (for confirmation of Mtb or exclusion of Mtb in case when NTM present).
breference standard for confirmed TB- diagnosis, defined as at least one positive culture (LJ or Mgit) confirmed as Mtb in speciation of per patient analysis; Mtb- negative
defined as all cultures negative (LJ and Mgit) for Mtb in per patient analysis, speciation results included.
Smear = Sputum smear microscopy after ZN-staining; LJ = Loewenstein-Jensen culture on solid media; Mgit = BACTEC MGIT 960 liquid culture.
doi:10.1371/journal.pone.0020458.t003
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sensitivity testing (DST) methods on liquid culture. There was also
no RIF resistance detected in any of the sputum samples processed
by the Xpert MTB/RIF Assay.
Discussion
Our study has several important and novel findings: Firstly, this
is a relatively large, controlled, comprehensive clinical validation
study of the diagnostic accuracy of the Xpert MTB/RIF assay in a
clinical cohort of patients suspected of having active TB from a TB
and HIV endemic area. More than 58% of the included subjects
were HIV-infected. Secondly, we present data showing that Xpert
MTB/RIF Assay has a very high sensitivity and specificity when
tested in the field compared to the current reference standard.
Thirdly, our data suggests that HIV status of patients does not
affect the performance of Xpert MTB/RIF Assay. Fourthly, Xpert
MTB/RIF Assay is very specific and is able to distinguish NTM
from Mtb. Fifthly, Xpert MTB/RIF Assay was positive in seven
patients who were sputum Mtb culture negative and were classified
as having ‘Clinical TB’. Finally, the assay was easy to perform,
gave results within two hours of sample processing, and there were
no operational difficulties during its usage.
Our data validate and support the findings of a technical
evaluation of the Xpert MTB/RIF Assay by Helb et al. [9] and a
multicenter assessment at five trial sites in Peru, Azerbaijan, South
Africa (Cape Town and Durban) and India by Boehme et al. [10].
While the sensitivity for smear positive samples was nearly 100%
in all three studies, our analysis showed a substantially lower
sensitivity in smear negative, culture positive samples than the two
previous studies (71% Helb et al., 90% Boehme et al. and 61% in
our study). Those differences might be explained by the following
aspects: The previous studies included samples under much more
selective conditions than our study which used samples from
sequential patients with suspected TB without any pre-selection.
Our study used concentrated sputum samples (which has been
reported to increase sensitivity of smear microscopy by up to 39%
[18]) and applied the revised WHO recommendation where one
single scanty sputum (1–9/100 fields) defines a smear positive
patient. The study from Boehme et al. [10] was performed on
fresh sputum samples, while we used frozen samples. However,
there is a controversy on whether the freezing process may cause
some degradation of DNA or as discussed by Helb et al. [9] and
Marlowe et al. [12] increases viscosity of the sample with improves
recovery of mycobacterial nucleic acids.
TB-control, especially in TB/HIV-endemic areas with poor
resources, is hampered by a lack of sensitivity and specificity of
sputum smear microscopy which is often the only diagnostic method
in place. In December 2010, WHO endorsed the Xpert MTB/RIF-
Assay for widespread use. Among other indications the assay has a
strong recommendation as initial diagnostic test in individuals with
suspected HIV-associated TB [14]. HIV-infected patients are
known to tend to have smear- negative sputum samples. This could
be confirmed by our data showing that 88.9% of TB patients with a
negative smear were HIV-infected. In this study we provide promise
that the Xpert MTB/RIF Assay has a high diagnostic accuracy in
HIV-positive patients (table 3) and that its performance is similar to
that in HIV-negative patients in our cohort.
In terms of specificity, we found potentially false positive sputa
from two patients detected by Xpert MTB/RIF Assay. One was a
patient from group ‘‘No TB’’ (C2) whose samples were tested
positive by Xpert MTB/RIF Assay. The fact that all three sputum
samples obtained from that patient were consistently positive in
the Xpert MTB/RIF Assay makes contamination an unlikely
explanation. Furthermore, the patient had a history of previous
TB, suggesting a sub clinical relapse or excretion of residual
persistent DNA from dead organisms, as possible reasons for the
positive result. The latter has been suggested to occur in treated
TB patients [19]. The other false positive sputum sample was from
a patient in the group ‘‘Clinical TB’’ (C2) who had NTM in
sputum culture. Mtb was later also confirmed by additional Hain
MTBDRplusH testing, which has a high specificity in clinical sputa
[20,21], and requires detection of katG and inhA amplification in
addition to rpoB [22]. Therefore, non-specific amplification by the
Xpert MTB/RIF Assay can be excluded. There was no history of
previous TB, but the patient presented in an advanced stage of
HIV immunosuppression (37 CD4+ T-cells/ml). It is possible that
concomitant infection or colonization with Mycobacterium fortuitum
which was detected in this patient’s culture inhibited the slower
growth of Mtb in culture, thereby preventing detection of the
patient’s TB by standard methods. If the reasoning in both these
cases is assumed as correct, the specificity of Xpert MTB/RIF
Assay would be 100% in our study.
Figure 1. Cycle threshold (Ct-value) versus grade of smear-
positivity. Ct versus degree of smear positivity, coded as negative = 0,
scanty = 1, 1+=2 etc (regression coefficient b=25.02, 95%CI =27.44 to
22.60). Ct for Xpert MTB/RIF Assay negatives was coded as 40.
doi:10.1371/journal.pone.0020458.g001
Figure 2. Cycle threshold (Ct-value) versus time to positivity in
MGIT liquid culture. Ct versus days from inoculation into MGIT liquid
culture to culture positivity as reported by the MGIT instrument
(b= 1.19, 95%CI = 0.98 to 1.39). Ct for Xpert MTB/RIF Assay negatives
was coded as 40.
doi:10.1371/journal.pone.0020458.g002
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Notwithstanding these exceptions, we are demonstrating here
for the first time that Xpert MTB/RIF Assay can accurately
differentiate between Mtb and NTM in clinical samples. This is
relevant since NTM are commonly found in large geographical
regions of Sub-Saharan Africa and are often picked up in sputum
cultures, especially MGIT liquid cultures. Approximately one
third of positive sputum cultures yield NTM in our setting in
Mbeya, Tanzania. In our experience, these NTM are rather
representing clinically insignificant concomitant flora of the
sputum or saliva and are rarely causing disease in neither
immunosuppressed nor immunocompetent individuals. Of 45
patients with NTM that were found in the groups of No TB (C2)
and Clinical TB (C2), one patient tested positive by Xpert MTB/
RIF Assay, resulting in a Xpert MTB/RIF Assay specificity of
97.8%. As described above there is good evidence to believe that
this case was a true TB case. Recent analytical studies with NTM
isolates by Helb et al. [9] and Blakemore et al. [23] indicated
specificity of 100% for the Xpert MTB/RIF Assay, however, in a
laboratory setting.
In our study Xpert MTB/RIF Assay detected seven TB cases
(9,1%) in the group of patients with Clinical TB (C2) which were
not picked up by any of the standard methods. Also, in the study
by Boehme et al. [10] 29,3% of patients were classified as clinical
TB cases who had no positive culture for Mtb but had a positive
Xpert MTB/RIF Assay result. Unfortunately these cases were not
delivered to final analysis. In our study these cases were followed
over 56 days and we are confident based on the clinical evidence
and the positive response to anti-TB treatment that they were true
TB cases, even if the final bacteriological proof is missing.
Because of the difficulty that an imperfect reference standard
poses when newer tests are evaluated that might be better than the
reference standard, we suggest to introduce the term, ‘‘extended’’
reference standard to enable an alternative comparison of new and
established assays. For our data the ‘extended’ reference standard
would include as TB-positives those cases with a positive smear or
culture and the seven Xpert MTB/RIF Assay positive cases with
reasonable clinical evidence of active TB. If this definition was
used the Xpert MTB/RIF Assay would have a higher or equal
sensitivity in each per sample analysis than any of the standard
methods alone or in combination. Thus sensitivity of Xpert MTB/
RIF Assay would be 84.2% (95%CI= 74.0% to 91.6%) in one spot
and 86.8% (95%CI= 77.1% to 93.5%) in one morning sputum
compared to 84.2% (95%CI=74.0% to 91.6%) and 79.0%
(95%CI=68.1% to 87.5%) respectively for all other methods
combined (smear plus solid and liquid culture), (data not shown).
For future clinical practice, it is however of paramount
importance to ascertain that these patients detected by Xpert
MTB/RIF Assay only are unambiguously true TB cases that were
missed by sputum culture and therefore a more thorough clinical
evaluation study which specifically addresses these cases would be
warranted. Furthermore, it will also be necessary to explore how
this new, promising assay can be made accessible to developing
countries. As with any new diagnostic test, the impact of Xpert
MTB/RIF Assay will depend on the reproducibility of the results
under actual field conditions, the manner and extent of their
introduction, the strength of the laboratories and the degree to
which access to appropriate therapy follows access to diagnosis.
Our data suggest that especially smear-negative TB patients could
benefit from the new assay in those areas where no culture is
available. Both aspects, that analysis of only one single spot sputum
sample by Xpert MTB/RIF-Assay can already reach reasonable
sensitivity and that the result would be available on the day of
sputum collection could result into more patients with active TB
being diagnosed, avoiding loss of patients and treatment delay in
those TB-suspects with a negative smear result who would
undergo two ineffective empirical courses of antibiotics before
TB-treatment would be initiated. Finally, this new sensitive and
rapid diagnostic assay could lead to the reduction of the infectious
pool and improvements in TB control.
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